FDA declines to approve Zealand Pharma’s hypoglycaemia therapy in infants
The US FDA has declined to approve Zealand Pharma's dasiglucagon for hypoglycaemia in infants with congenital hyperinsulinism (CHI).
The US FDA has declined to approve Zealand Pharma's dasiglucagon for hypoglycaemia in infants with congenital hyperinsulinism (CHI).
What's Your Reaction?
